BIOMARIN PHARMACEUTICAL INC (BMRN) Spending and interest coverage
- R&D / revenue · 12 months: Value 28.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 6.32%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 28.99% | Research and development expense / revenue. Period ending 2026-06-30. $987.64M ÷ $3.41B × 100 ≈ 28.99% |
| Stock-based compensation / revenue · 12 months | 6.32% | Share-based compensation / revenue. Period ending 2026-06-30. $215.33M ÷ $3.41B × 100 ≈ 6.32% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 987.64M USD | Research and Development Expense |
| Revenue | 3.41B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 215.33M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 149.26M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $987.64M | $3.41B | $215.33M | $149.26M | (m) | 28.99% | 6.32% | (m) | (m) |
| 2026-03-31 | $942.00M | $3.24B | $187.17M | $315.23M | (m) | 29.05% | 5.77% | (m) | (m) |
| 2025-12-31 | $921.93M | $3.22B | $181.41M | $409.48M | (m) | 28.62% | 5.63% | (m) | (m) |
| 2025-09-30 | $903.03M | $3.09B | $186.41M | $615.50M | (m) | 29.19% | 6.03% | (m) | (m) |
| 2025-06-30 | $678.45M | $3.06B | $180.64M | $776.08M | (m) | 22.15% | 5.90% | (m) | (m) |
| 2025-03-31 | $700.93M | $2.95B | $181.02M | $619.64M | (m) | 23.76% | 6.14% | (m) | (m) |
| 2024-12-31 | $747.18M | $2.85B | $201.57M | $484.21M | (m) | 26.18% | 7.06% | (m) | (m) |
| 2024-09-30 | $779.92M | $2.75B | $204.51M | $322.41M | (m) | 28.33% | 7.43% | (m) | (m) |
| 2024-06-30 | $786.34M | $2.59B | $209.41M | $239.04M | (m) | 30.38% | 8.09% | (m) | (m) |
| 2024-03-31 | $779.91M | $2.47B | $211.65M | $184.16M | $17.18M | 31.55% | 8.56% | 10.72× | Reported |
| 2023-12-31 | $746.77M | $2.42B | $207.10M | $158.10M | $17.34M | 30.87% | 8.56% | 9.12× | Reported |
| 2023-09-30 | $713.27M | $2.31B | $198.98M | $119.38M | $14.86M | 30.87% | 8.61% | 8.03× | Reported |
| 2023-06-30 | $679.79M | $2.23B | $205.25M | $91.30M | $15.76M | 30.42% | 9.19% | 5.79× | Reported |
| 2023-03-31 | $660.62M | $2.17B | $202.17M | $71.58M | $15.87M | 30.40% | 9.30% | 4.51× | Reported |
| 2022-12-31 | $649.61M | $2.10B | $196.31M | $149.56M | $15.97M | 30.99% | 9.37% | 9.37× | Reported |
| 2022-09-30 | $637.95M | $2.01B | $193.47M | $108.18M | $16.19M | 31.77% | 9.63% | 6.68× | Reported |
| 2022-06-30 | $637.99M | $1.91B | $187.83M | $57.38M | $15.38M | 33.37% | 9.83% | 3.73× | Reported |
| 2022-03-31 | $640.90M | $1.88B | $195.59M | $29.90M | $15.34M | 34.10% | 10.41% | 1.95× | Reported |
| 2021-12-31 | $628.79M | $1.85B | $197.26M | $-82.34M | $15.34M | 34.06% | 10.68% | -5.37× | Reported |
| 2021-09-30 | $624.37M | $1.85B | $200.96M | $-61.30M | $16.24M | 33.78% | 10.87% | -3.77× | Reported |
| 2021-06-30 | $613.55M | $1.92B | $202.10M | $-64.02M | $21.97M | 32.01% | 10.54% | -2.91× | Reported |
| 2021-03-31 | $634.58M | $1.84B | $192.22M | $-116.64M | $26.20M | 34.41% | 10.42% | -4.45× | Reported |
| 2020-12-31 | $628.12M | $1.86B | $189.71M | $-36.77M | $29.31M | 33.76% | 10.20% | -1.25× | Reported |
| 2020-09-30 | $644.26M | $1.86B | $180.23M | $-1.09M | $31.49M | 34.59% | 9.68% | -0.03× | Reported |
| 2020-06-30 | $670.17M | $1.85B | $169.23M | $58.86M | $24.83M | 36.28% | 9.16% | 2.37× | Reported |
| 2020-03-31 | $673.67M | $1.81B | $164.10M | $58.45M | $23.65M | 37.31% | 9.09% | 2.47× | Reported |
| 2019-12-31 | $715.01M | $1.70B | $159.87M | $-100.46M | $23.46M | 41.96% | 9.38% | -4.28× | Reported |
| 2019-09-30 | $717.59M | $1.60B | $158.32M | $-129.44M | $24.28M | 44.77% | 9.88% | -5.33× | Reported |
| 2019-06-30 | $706.03M | $1.53B | $156.19M | $-149.19M | $33.47M | 46.04% | 10.19% | -4.46× | Reported |
| 2019-03-31 | $695.97M | $1.52B | $154.97M | $-133.10M | $38.83M | 45.83% | 10.21% | -3.43× | Reported |
| 2018-12-31 | $696.33M | $1.49B | $148.82M | $-123.52M | $43.66M | 46.70% | 9.98% | -2.83× | Reported |
| 2018-09-30 | $689.55M | $1.50B | $145.85M | $-27.33M | $47.58M | 46.08% | 9.75% | -0.57× | Reported |
| 2018-06-30 | $682.24M | $1.44B | $144.70M | $-25.32M | $46.34M | 47.42% | 10.06% | -0.55× | Reported |
| 2018-03-31 | $649.70M | $1.38B | $146.20M | $-38.86M | $44.15M | 46.97% | 10.57% | -0.88× | Reported |
| 2017-12-31 | $610.75M | $1.31B | $140.26M | $-14.70M | $42.71M | 46.49% | 10.68% | -0.34× | Reported |
| 2017-09-30 | $617.39M | $1.26B | $144.10M | $-162.37M | $40.77M | 49.18% | 11.48% | -3.98× | Reported |
| 2017-06-30 | $624.12M | $1.20B | $141.34M | $-208.73M | $39.87M | 51.96% | 11.77% | -5.24× | Reported |
| 2017-03-31 | $648.12M | $1.18B | $135.14M | $-742.72M | $39.77M | 54.75% | 11.42% | -18.67× | Reported |
| 2016-12-31 | $661.90M | $1.12B | $134.64M | $-803.43M | $39.50M | 59.27% | 12.06% | -20.34× | Reported |
| 2016-09-30 | $662.78M | $1.04B | $127.79M | $-612.49M | $39.10M | 63.44% | 12.23% | -15.66× | Reported |
| 2016-06-30 | $660.66M | $973.71M | $123.40M | $-634.28M | $38.57M | 67.85% | 12.67% | -16.45× | Reported |
| 2016-03-31 | $651.52M | $923.71M | $119.01M | $-125.76M | $38.63M | 70.53% | 12.88% | -3.26× | Reported |
| 2015-12-31 | $634.81M | $889.89M | $111.53M | $-110.70M | $38.24M | 71.33% | 12.53% | -2.89× | Reported |
| 2015-09-30 | $600.75M | $893.78M | $117.45M | $-270.78M | $38.11M | 67.21% | 13.14% | -7.11× | Reported |
| 2015-06-30 | $567.65M | $861.49M | $107.84M | $-177.65M | $37.78M | 65.89% | 12.52% | -4.70× | Reported |
| 2015-03-31 | $517.45M | $802.75M | $94.68M | $-132.29M | $37.00M | 64.46% | 11.79% | -3.58× | Reported |
| 2014-12-31 | $461.54M | $751.04M | $88.23M | $-92.89M | $36.64M | 61.45% | 11.75% | -2.54× | Reported |
| 2014-09-30 | $416.87M | $667.06M | $78.79M | $-86.44M | $35.04M | 62.49% | 11.81% | -2.47× | Reported |
| 2014-06-30 | $379.24M | $627.09M | $75.12M | $-148.37M | $26.45M | 60.48% | 11.98% | -5.61× | Reported |
| 2014-03-31 | $357.20M | $572.11M | $71.94M | $-149.54M | $17.83M | 62.44% | 12.57% | -8.39× | Reported |
| 2013-12-31 | $354.78M | $548.49M | $66.18M | $-156.01M | $10.45M | 64.68% | 12.07% | -14.93× | Reported |
| 2013-09-30 | $341.83M | $533.55M | $54.56M | $-150.60M | $4.78M | 64.07% | 10.23% | -31.48× | Reported |
| 2013-06-30 | $319.98M | $524.79M | $49.76M | $-110.37M | $6.09M | 60.97% | 9.48% | -18.11× | Reported |
| 2013-03-31 | $312.13M | $512.00M | $47.69M | $-121.27M | $7.42M | 60.96% | 9.32% | -16.35× | Reported |
| 2012-12-31 | $302.22M | $500.72M | $47.34M | $-110.22M | $7.64M | 60.36% | 9.45% | -14.43× | Reported |
| 2012-09-30 | $275.76M | $476.63M | $46.60M | $-84.75M | $7.53M | 57.86% | 9.78% | -11.26× | Reported |
| 2012-06-30 | $268.13M | $461.94M | $46.40M | $-89.77M | $7.86M | 58.04% | 10.04% | -11.43× | Reported |
| 2012-03-31 | $243.19M | $448.55M | $44.91M | $-58.05M | $8.13M | 54.22% | 10.01% | -7.14× | Reported |
| 2011-12-31 | $214.37M | $441.36M | $43.91M | $-33.89M | $8.35M | 48.57% | 9.95% | -4.06× | Reported |
| 2011-09-30 | $198.66M | $435.13M | $42.56M | $-15.80M | $8.90M | 45.66% | 9.78% | -1.78× | Reported |
| 2011-06-30 | $179.45M | $419.45M | $41.07M | $-2.23M | $9.48M | 42.78% | 9.79% | -0.23× | Reported |
| 2011-03-31 | $162.23M | $400.77M | $39.91M | $48.00K | $10.04M | 40.48% | 9.96% | 0.00× | Reported |
| 2010-12-31 | $147.31M | $376.27M | $38.36M | $544.00K | $10.33M | 39.15% | 10.20% | 0.05× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $115.12M | $324.66M | $36.01M | $16.43M | $14.09M | 35.46% | 11.09% | 1.17× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $93.29M | $296.49M | $28.34M | $39.76M | $16.39M | 31.46% | 9.56% | 2.43× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |